Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
Published version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The lack of second-line treatment for relapsed ovarian cancer necessitates the development of improved combination therapies. Targeted therapy and immunotherapy each confer clinical benefit, albeit limited as monotherapies. Ovarian cancer is not particularly responsive to immune checkpoint blockade, so combination with a complementary therapy may be beneficial. Recent studies have revealed that a DNA methyl transferase inhibitor, azacytidine, alters expression of immunoregulatory genes in ovarian cancer. In this study, the antitumor effects of a related DNA methyl transferase inhibitor, decitabine (DAC), were demonstrated in a syngeneic murine ovarian cancer model. Low-dose DAC treatment increases the expression of chemokines that recruit NK cells and CD8(+) T cells, promotes their production of IFNγ and TNFα, and extends the survival of mice bearing subcutaneous or orthotopic tumors. While neither DAC nor immune checkpoint blockade confers durable responses as a monotherapy in this model, the efficacy of anti-CTLA-4 was potentiated by combination with DAC. This combination promotes differentiation of naïve T cells into effector T cells and prolongs cytotoxic lymphocyte responses as well as mouse survival. These results suggest that this combination therapy may be worthy of further consideration for improved treatment of drug-resistant ovarian cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“reconfiguration of the TME (Luo et al., 2018; Travers et al., 2019; Wanget al., 2015; Yu et al., 2019) in support of anticancer immunity or increased sensitivity to CTLA4-or PD-1 blockage”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Wang et al., 2015
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Improving the immunogenicity of tumors represents one approach to overcome a tumor's evasion of the immune system (2).”
BackgroundSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 9×
“org Cancer Immunol Res; 3(9) September 2015 OF3”
BackgroundInfluentialJones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515 · cited 1×
“The effects of these drugs are thought to be particularly profound in the context of cancer stem cells (11) and drug tolerance heterogeneity (12).”
BackgroundCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×
“Immunotherapy can address disease that is refractory to conventional treatment options and represents an exciting new modality to achieve durable patient responses (1).”
BackgroundA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709 · cited 1×
“The therapeutic benefits of targeting checkpoint blockade have been validated in patients with advanced solid tumors (8), including ovarian cancer (9).”
BackgroundSato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · cited 7×
“GITR ligation enhances the infiltration and activity of effector T cells (33) and NK cells (22, 34) and generates effector T cells that are resistant to the immunosuppressive effects of Tregs (35).”
BackgroundInfluentialMonoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Cancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205 · cited 1×
“Epigenetic modifiers have gained considerable attention of late in the pursuit of antitumor compounds that do not impart the harsh side effects of cytotoxic chemotherapeutics, as epigenetic patterns differ between normal cells and cancer cells, enabling discrimination (10).”
Background
Cited by
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
“Thus, epigenetic reprogramming can unlock the repressed TH1-type chemokines, IFN signature genes, and tumor antigen expression andmay therefore condition tumor from poor T cell infiltration to rich T cell infiltration and ultimately potentiate PD blockade therapy (94, 95, 108).”
BackgroundChemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
“Where studied in vivo, methyltransferase inhibitors increased expression of MHC I and MHC I pathway components in multiple types of cancers in patients (182, 245) and a xenograft model (192).”
BackgroundInfluentialProspects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Ghoneim, H. E., Fan, Y., Moustaki, A., Abdelsamed, H. A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G., Thomas, P. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.007 · Cited by 781
“In addition to exploiting natural mechanisms of epigenetic reversal, it may be possible to directly reverse epigenetic modifications with existing chemotherapeutics (Chiappinelli et al., 2016; Roulois et al., 2015; Wang et al., 2015).”
Metadata
- Authors
- Wang, L., Amoozgar, Z., Huang, J., Saleh, M. H., Xing, D., Orsulic, S., & Goldberg, M. S.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Johns Hopkins University (US)
- 3Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
- Venue
- Cancer Immunology Research
- Published
- 2015-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 1030-1041
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2136708520
- Cited by
- 173
- References
- 50
- Citations by year
- 2026: 5 · 2025: 19 · 2024: 10 · 2023: 16 · 2022: 20 · 2021: 23 · 2020: 15 · 2019: 17 · 2018: 14 · 2017: 20 · 2016: 12 · 2015: 2
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Peking University
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- decitabine, hypomethylating agents, ovarian cancer, CTLA-4 blockade, immune checkpoint blockade, combination therapy, lymphocyte migration, natural killer cells, CD8+ T cells, chemokines, interferon-gamma, TNF-α, T cell differentiation, cytotoxic lymphocytes, drug-resistant cancer, syngeneic murine model
- MeSH terms
- Decitabine, Animals, Antineoplastic Agents, Ascitic Fluid, Azacitidine, Cell Movement, Cell Transformation, Neoplastic, Female, Humans, Immunotherapy, Killer Cells, Natural, Lymph Nodes, Ovarian Neoplasms, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Cytokines, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Xenograft Model Antitumor Assays, Mice, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. https://app.cochat.ai/papers/10.1158/2326-6066.cir-15-0073
- The paper
- Wang, L., Amoozgar, Z., Huang, J., Saleh, M. H., Xing, D., Orsulic, S., & Goldberg, M. S. (2015). Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-15-0073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.